Genetics Companies End Patent Dispute Over HPV Test

Law360, New York (January 13, 2006, 12:00 AM EST) -- Two feuding genetic testing product companies have ended a patent dispute over testing methods used to detect risk for the human papilloma virus, a common sexually transmitted infection that causes cervical cancer.

The settlement agreement comes about three months after Third Wave Technologies Inc. sued the Maryland-based Digene Corporation, seeking declaratory judgment supporting Third Wave's right to sell its HPV products.

In a press release on Friday, Digene stated that Third Wave had dismissed the suit without prejudice. Representatives from both companies could not be reached...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.